Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics develops cancer treatments, including immune cell therapies and small molecule drugs, for patients with blood cancers and solid tumors. It last closed at $0.33 on Nov 17, down 5.13% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From TPST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on TPST in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $0.33.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 24 | HC Wainwright & Co. | Maintained | Buy | $7 |
Technical Analysis
The stock is 36% below its 20 day and 101% below its 50 day average. It is 316% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot at $0.32, and the nearest resistance the Pivot R1 at $0.34.
| RSI (14) | 23.20 | Oversold below 30 | Oversold |
| MACD | -0.09 | Below its signal line | Bearish |
| Stochastic | 9.3 | Near the bottom of its range | Oversold |
| ADX (14) | 28.3 | Trending down | |
| Williams %R | -94.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -128.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −30.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.05 | Typical daily range, 16.4% of price |
| RSI (14) | 22.35 | Oversold below 30 | Oversold |
| MACD | -0.44 | Above its signal line | Bullish |
| Stochastic | 1.8 | Near the bottom of its range | Oversold |
| ADX (14) | 25.8 | Trending down | |
| Williams %R | -98.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -154.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −59.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.24 | Typical daily range, 71.8% of price |
What happened before
See how TPST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How TPST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
Whale Options Flow
90DNo whale options trades in TPST in the last 90 days.
TPST Institutional Ownership
Full report →- ●10 buying vs 9 selling
- ▼Held by funds -2.4 pts
- ▲Funds holding +3
- ▼Superinvestors: 0 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 24 | 21 | +14.3% |
| In funds' top 10 | 1 | 2 | −50.0% |
| Held by funds | 4.1% | 6.5% | −2.4 pts |
| New / increased | 8 / 2 | 4 / 5 | +11.1% |
| Reduced / sold out | 4 / 5 | 3 / 5 | +12.5% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TPST is in one of them and how their past TPST trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TPST in an article yet. Here's the latest on the wider market.
About Tempest Therapeutics
Tempest Therapeutics is a biotechnology company based in Brisbane, California, that develops treatments for cancer. Its pipeline includes cell therapies that use engineered immune cells to target tumors, including a candidate for multiple myeloma, a blood cancer. It also develops small molecule drugs, including one being prepared for late-stage testing in liver cancer and another for people with a rare inherited condition that raises the risk of certain cancers. Its candidates are still in development and not approved for sale, and they are aimed at patients with these cancers and conditions.
- Headquarters
- Brisbane, CA
